EUVIMEDEUVIMED entdecken
Crossref

Repeat stereotactic radiosurgery for recurrent brain metastases: safety and durable local control in a single-centre series of 132 metastases

Luis Aznar-García, Bruno E Zambrana-Moreno

Clinical and Translational Oncology · 12.11.2026

DOI: 10.1007/s12094-026-04573-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 12.11.2026. Verfasst von Luis Aznar-García und 1 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Nottingham University Hospitals, Hucknall Rd, Nottingham, NG5 1PB, UK. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Local progression (LP) after stereotactic radiosurgery (SRS) for brain metastases (BM) presents a therapeutic challenge and evidence for repeat SRS (ReSRS) is limited. This study reports outcomes of second (SRS2) and third (SRS3) SRS courses for recurrent BM. METHODS: We retrospectively analysed patients treated with ReSRS between 2016 and 2025 at our institution. Clinical, radiological, and dosimetric variables were collected. Local progression-free survival (L-PFS), radionecrosis, and radiological response were analysed. Predictors of LP and radionecrosis were evaluated with univariate and multivariate analyses. RESULTS: 132 BM in 96 patients were included. SRS2 (132 BM) and SRS3 (14 BM) achieved 12-month local control rates of 78.7 and 67.0%, respectively. Median L-PFS after SRS2 was 47.1 months. Independent predictors of LP after SRS2 were BED₁₂Gy < 53.6 Gy at SRS1 (p = 0.014) and fractionated SRS2 (p = 0.042), but not confirmed with further analysis. The incidence of radiological radionecrosis following SRS2 was 40.9%, with rates of 28.0%, 36.4, and 38.6% at 6, 12, and 24 months, respectively. Symptomatic radionecrosis occurred in 14.6% of patients, and all of them improved with corticosteroid treatment. Clinical improvement was observed in 42.2%, while 92.4% showed radiological stability/response after SRS2. No treatment-related deaths were observed. CONCLUSIONS: ReSRS is a safe and effective salvage approach for recurrent BM offering durable local control, favourable clinical outcomes, and acceptable adverse events. Prospective studies are needed to refine patient selection and improve risk stratification.

Schlagwörter

Stichwörter der Autor:innen

Brain metastasesRadionecrosisRe-irradiationSRSStereotactic radiosurgery

Autor:innen und Institutionen

  • Oncology Department, Nottingham University Hospitals, Hucknall Rd, Nottingham, NG5 1PB, UK.
  • Oncology Department, Nottingham University Hospitals, Hucknall Rd, Nottingham, NG5 1PB, UK. dr.brunozambrana@gmail.com.
  • Radiation Oncology Department, Hospital Universitario HM Sanchinarro, Oña 10, 28050, Madrid, Spain. dr.brunozambrana@gmail.com.

Zitieren

APA

Aznar-García, L., & Zambrana-Moreno, B. E. (2026). Repeat stereotactic radiosurgery for recurrent brain metastases: safety and durable local control in a single-centre series of 132 metastases. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04573-5

Vancouver

Aznar-García L, Zambrana-Moreno BE. Repeat stereotactic radiosurgery for recurrent brain metastases: safety and durable local control in a single-centre series of 132 metastases. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04573-5

BibTeX
@article{AznarGarca2026,
  author = {Aznar-García, Luis and Zambrana-Moreno, Bruno E},
  title = {Repeat stereotactic radiosurgery for recurrent brain metastases: safety and durable local control in a single-centre series of 132 metastases},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04573-5}
}
Kostenlos starten →